Privium Fund Management B.V. Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA)

Privium Fund Management B.V. decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 41.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,261 shares of the company's stock after selling 16,600 shares during the quarter. Moderna comprises about 0.7% of Privium Fund Management B.V.'s portfolio, making the stock its 29th biggest holding. Privium Fund Management B.V.'s holdings in Moderna were worth $2,723,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Cedar Wealth Management LLC grew its holdings in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock worth $31,000 after buying an additional 90 shares in the last quarter. Commerzbank Aktiengesellschaft FI grew its holdings in shares of Moderna by 1.7% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company's stock valued at $660,000 after purchasing an additional 93 shares during the period. CVA Family Office LLC grew its holdings in shares of Moderna by 21.6% in the second quarter. CVA Family Office LLC now owns 541 shares of the company's stock valued at $64,000 after purchasing an additional 96 shares during the period. Claro Advisors LLC grew its holdings in shares of Moderna by 2.0% in the second quarter. Claro Advisors LLC now owns 5,546 shares of the company's stock valued at $659,000 after purchasing an additional 108 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Moderna by 32.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company's stock valued at $47,000 after purchasing an additional 116 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MRNA. JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $96.00 to $88.00 and set a "neutral" rating for the company in a report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a "sell" rating to a "hold" rating and dropped their price objective for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. HSBC raised shares of Moderna from a "reduce" rating to a "hold" rating and set a $82.00 price objective for the company in a report on Wednesday. Piper Sandler reaffirmed an "overweight" rating and issued a $157.00 target price (down previously from $214.00) on shares of Moderna in a research report on Friday, August 2nd. Finally, Barclays decreased their target price on shares of Moderna from $168.00 to $155.00 and set an "overweight" rating on the stock in a research report on Friday, August 2nd. Ten analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $123.79.

Insider Buying and Selling

In related news, CFO James M. Mock sold 1,321 shares of the company's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO James M. Mock sold 1,321 shares of the company's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Noubar Afeyan sold 202,832 shares of the company's stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the sale, the director now owns 1,528,557 shares in the company, valued at $226,746,145.38. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 330,736 shares of company stock worth $46,330,112. Company insiders own 15.70% of the company's stock.

Moderna Stock Down 0.2 %

Shares of MRNA traded down $0.19 during mid-day trading on Friday, hitting $77.40. 3,591,705 shares of the company's stock were exchanged, compared to its average volume of 4,084,163. The company has a market cap of $29.75 billion, a price-to-earnings ratio of -4.94 and a beta of 1.67. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The stock's 50-day moving average is $104.62 and its 200-day moving average is $113.18.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analysts' expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business's quarterly revenue was down 29.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.62) earnings per share. On average, sell-side analysts anticipate that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.